A Phase 1b/2 Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Viracta Therapeutics

Protocol Number
VT3996-201

To Learn More Call
(201)-510-0950